MP18-10 ONCOLOGIC OUTCOMES AFTER HEMIABLATION THERAPY FOR LOCALIZED PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy1 Apr 2016MP18-10 ONCOLOGIC OUTCOMES AFTER HEMIABLATION THERAPY FOR LOCALIZED PROSTATE CANCER Estefania Linares Espinos, Jose I. Perez-Reggeti, Eric Barret, Arjun Sivaraman, Rafael Sanchez-Salas, Marc Galiano, François Rozet, Dominique Prapotnich, Nathalie Cathala, Annick Mombet, and Xavier Cathelineau Estefania Linares EspinosEstefania Linares Espinos More articles by this author , Jose I. Perez-ReggetiJose I. Perez-Reggeti More articles by this author , Eric BarretEric Barret More articles by this author , Arjun SivaramanArjun Sivaraman More articles by this author , Rafael Sanchez-SalasRafael Sanchez-Salas More articles by this author , Marc GalianoMarc Galiano More articles by this author , François RozetFrançois Rozet More articles by this author , Dominique PrapotnichDominique Prapotnich More articles by this author , Nathalie CathalaNathalie Cathala More articles by this author , Annick MombetAnnick Mombet More articles by this author , and Xavier CathelineauXavier Cathelineau More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2711AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Focal therapy was developed in order to limit side effects of conventional prostate cancer (PCa) treatments. We aimed to assess oncologic outcomes after focal thermal ablative primary treatment. METHODS Between January 2009 to August 2015, 277 patients underwent primary thermal hemiablation for localized PCa at our institution. Energy used was either cryotherapy or high intensity focused ultrasound (HIFU) or vascular-targeted photodynamic therapy (VTP). Inclusion criteria for hemiablation treatment were PSA<15ng/dl, Gleason ≤7, unilateral disease and index lesion <10mm and MRI prior to biopsy ≤T2b. We selected patients with post-treatment prostate biopsy and 12 months minimum follow-up. Patients were followed postoperatively with PSA, MRI-imaging and 12-core TRUS protocol biopsy, at 6-12 months. Failure was defined as any positive biopsy in the treated lobe. Cross-tabs applying chi-square were used to assess relationships among categorical variables. A p value <0.05 was considered statistically significant. Statistical analysis was performed using SPSS v21. RESULTS At one year follow-up, 229 patients had post-treatment control biopsy with 48 not available. Among them, 110, 89 and 30 patients underwent a hemiablation of the prostate using cryotherpy, HIFU and VTP respectively. A total of 55 patients had biopsy-proven cancer at follow-up. With a mean age of 65,5 ± 6,7 years, 43 were D'Amico Low risk and 12 Intermediate risk at diagnosis. Initial PSA was 7,44 ± 2,93 ng/dl, 47 Gleason 3+3 and 8 Gleason 3+4. Thirty (27%), 13 (17%) and 12 (40%) had biopsy proven cancer after primary focal cryotherapy, HIFU and VTP, respectively. Residual cancer in the treated side was present in 41 patients (15 bilateral), considered as failure to treatment (18%). De novo contralateral disease was diagnosed in 14 patients. Residual disease had a median core length of 4mm (3-13) and a median number of 2 (1-3) positive cores. No difference were observed in focal treatment failure between primary focal energy modalities (table 1). CONCLUSIONS Short-term data show promising oncologic outcomes in the focal therapy primary setting with 18% failure rate. Focal ablative therapy is an effective treatment option for the primary management of PCa, with no proven differences in failure rates between energy modalities. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e196 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Estefania Linares Espinos More articles by this author Jose I. Perez-Reggeti More articles by this author Eric Barret More articles by this author Arjun Sivaraman More articles by this author Rafael Sanchez-Salas More articles by this author Marc Galiano More articles by this author François Rozet More articles by this author Dominique Prapotnich More articles by this author Nathalie Cathala More articles by this author Annick Mombet More articles by this author Xavier Cathelineau More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...